Contents

Kinh Nghiệm về Virus shedding là gì Mới Nhất

Bạn đang tìm kiếm từ khóa Virus shedding là gì được Update vào lúc : 2022-02-08 04:25:57 . Với phương châm chia sẻ Thủ Thuật về trong nội dung bài viết một cách Chi Tiết 2022. Nếu sau khi Read Post vẫn ko hiểu thì hoàn toàn có thể lại phản hồi ở cuối bài để Admin lý giải và hướng dẫn lại nha.

    Brief CommunicationPublished: 15 April 2022

Temporal dynamics in viral shedding and transmissibility of COVID-19

    Xi He1na1,Eric H. Y. Lau ORCID: orcid.org/0000-0002-6688-96372na1,Peng Wu2,Xilong Deng1,Jian Wang1,Xinxin Hao2,Yiu Chung Lau2,Jessica Y. Wong2,Yujuan Guan1,Xinghua Tan1,Xiaoneng Mo1,Yanqing Chen1,Baolin Liao1,Weilie Chen1,Fengyu Hu1,Qing Zhang1,Mingqiu Zhong1,Yanrong Wu1,Lingzhai Zhao1,Fuchun Zhang1,Benjamin J. Cowling ORCID: orcid.org/0000-0002-6297-71542na2,Fang Li1na2 &Gabriel M. Leung ORCID: orcid.org/0000-0002-2503-62832na2

Nature Medicine volume26,pages 672675 (2022)Cite this article

Nội dung chính

    Temporal dynamics in viral shedding and transmissibility of COVID-19Sources of dataStatistical analysisEthics approvalReporting SummaryData availabilityCode availabilityChange history07 August 2020AcknowledgementsAuthor informationAffiliationsContributionsCorresponding authorEthics declarationsCompeting interestsAdditional informationExtended dataExtended Data Fig. 1 Inferred infectiousness profile.Extended Data Fig. 2 Simulated serial intervals.Extended Data Fig. 3 Simulated proportions of negative serial intervals.Supplementary informationSupplementary InformationReporting SummarySupplementary Data 1Supplementary Software 1Rights and permissionsAbout this articleCite this articleShare this articleFurther readingPreventing COVID-19 outbreaks through surveillance testing in healthcare facilities: a modelling studyOptimal strategies to screen health care workers for COVID-19 in the US: a cost-effectiveness analysisModelling upper respiratory viral load dynamics of SARS-CoV-2Model-based evaluation of alternative reactive class closure strategies against COVID-19SARS-CoV-2 viability on sports equipment is limited, and dependent on material compositionVideo liên quan

    872k Accesses

    1856 Citations

    16399 Altmetric

    Metrics details

Subjects

    Disease preventionEpidemiologyInfectious diseasesPublic health

Matters Arising to this article was published on 17 August 2022

An Author Correction to this article was published on 07 August 2022

This article has been updated

Abstract

We report temporal patterns of viral shedding in 94 patients with laboratory-confirmed COVID-19 and modeled COVID-19 infectiousness profiles from a separate sample of 77 infectorinfectee transmission pairs. We observed the highest viral load in throat swabs the time of symptom onset, and inferred that infectiousness peaked on or before symptom onset. We estimated that 44% (95% confidence interval, 3057%) of secondary cases were infected during the index cases presymptomatic stage, in settings with substantial household clustering, active case finding and quarantine outside the home. Disease control measures should be adjusted to account for probable substantial presymptomatic transmission.

Download PDF

Main

SARS-CoV-2, the causative agent of COVID-19, spreads efficiently, with a basic reproductive number of 2.2 to 2.5 determined in Wuhan1,2. The effectiveness of control measures depends on several key epidemiological parameters (Fig. 1a), including the serial interval (duration between symptom onsets of successive cases in a transmission chain) and the incubation period (time between infection and onset of symptoms). Variation between individuals and transmission chains is summarized by the incubation period distribution and the serial interval distribution, respectively. If the observed mean serial interval is shorter than the observed mean incubation period, this indicates that a significant portion of transmission may have occurred before infected persons have developed symptoms. Significant presymptomatic transmission would probably reduce the effectiveness of control measures that are initiated by symptom onset, such as isolation, contact tracing and enhanced hygiene or use of face masks for symptomatic persons.

Fig. 1: Transmission of infectious diseases.

a, Schematic of the relation between different time periods in the transmission of infectious disease. b, Human-to-human transmission pairs of SAR-CoV-2 virus (N = 77). We assumed a maximum exposure window of 21 days prior to symptom onset of the secondary cases. Detailed information on the transmission pairs and the source of information is summarized in Supplementary Tables 2 and 3. c, Estimated serial interval distribution (top), inferred infectiousness profile (middle) and assumed incubation period (bottom) of COVID-19.

Full size image

SARS (severe acute respiratory syndrome) was notable, because infectiousness increased around 710 days after symptom onset3,4. Onward transmission can be substantially reduced by containment measures such as isolation and quarantine (Fig. 1a)5. In contrast, influenza is characterized by increased infectiousness shortly around or even before symptom onset6.

In this study, we compared clinical data on virus shedding with separate epidemiologic data on incubation periods and serial intervals between cases in transmission chains, to draw inferences on infectiousness profiles.

Among 94 patients with laboratory-confirmed COVID-19 admitted to Guangzhou Eighth Peoples Hospital, 47/94 (50%) were male, the median age was 47 years and 61/93 (66%) were moderately ill (with fever and/or respiratory symptoms and radiographic evidence of pneumonia), but none were classified as severe or critical on hospital admission (Supplementary Table 1).

A total of 414 throat swabs were collected from these 94 patients, from symptom onset up to 32 days after onset. We detected high viral loads soon after symptom onset, which then gradually decreased towards the detection limit about day 21. There was no obvious difference in viral loads across sex, age groups and disease severity (Fig. 2).

Fig. 2: Temporal patterns of viral shedding.

Viral load (threshold cycle (Ct) values) detected by RTPCR (PCR with reverse transcription) in throat swabs from patients infected with SARS-CoV-2 (N = 94), overall and stratified by disease severity, sex, age group and link to Hubei province. The detection limit was Ct = 40, which was used to indicate negative samples. The thick lines show the trend in viral load, using smoothing splines. We added some noise to the data points to avoid overlaps.

Full size image

Separately, based on 77 transmission pairs obtained from publicly available sources within and outside mainland China (Fig. 1b and Supplementary Table 2), the serial interval was estimated to have a mean of 5.8 days (95% confidence interval (CI), 4.86.8 days) and a median of 5.2 days (95% CI, 4.16.4 days) based on a fitted gamma distribution, with 7.6% negative serial intervals (Fig. 1c). Assuming an incubation period distribution of mean 5.2 days from a separate study of early COVID-19 cases1, we inferred that infectiousness started from 12.3 days (95% CI, 5.917.0 days) before symptom onset and peaked symptom onset (95% CI, 0.90.9 days) (Fig. 1c). We further observed that only <0.1% of transmission would occur before 7 days, 1% of transmission would occur before 5 days and 9% of transmission would occur before 3 days prior to symptom onset. The estimated proportion of presymptomatic transmission (area under the curve) was 44% (95% CI, 3057%). Infectiousness was estimated to decline quickly within 7 days. Viral load data were not used in the estimation but showed a similar monotonic decreasing pattern.

In sensitivity analysis, using the same estimating procedure but holding constant the start of infectiousness from 5, 8 and 11 days before symptom onset, infectiousness was shown to peak 2 days before to 1 day after symptom onset, and the proportion of presymptomatic transmission ranged from 37% to 48% (Extended Data Fig. 1).

Finally, simulation showed that the proportion of short serial intervals (for example, <2 days) would be larger if infectiousness were assumed to start before symptom onset (Extended Data Fig. 2). Given the 7.6% negative serial intervals estimated from the infectorinfectee paired data, start of infectiousness least 2 days before onset and peak infectiousness 2 days before to 1 day after onset would be most consistent with this observed proportion (Extended Data Fig. 3).

Here, we used detailed information on the timing of symptom onsets in transmission pairs to infer the infectiousness profile of COVID-19. We showed substantial transmission potential before symptom onset. Of note, most cases were isolated after symptom onset, preventing some post-symptomatic transmission. Even higher proportions of presymptomatic transmission of 48% and 62% have been estimated for Singapore and Tianjin, where active case finding was implemented7. Places with active case finding would tend to have a higher proportion of presymptomatic transmission, mainly due to quick quarantine of close contacts and isolation, thus reducing the probability of secondary spread later on in the course of illness. In a rapidly expanding epidemic wherein contact tracing/quarantine and perhaps even isolation are no longer feasible, or in locations where cases are not isolated outside the home, we should therefore observe a lower proportion of presymptomatic transmission.

Our analysis suggests that viral shedding may begin 5 to 6 days before the appearance of the first symptoms. After symptom onset, viral loads decreased monotonically, consistent with two recent studies8,9. Another study from Wuhan reported that virus was detected for a median of 20 days (up to 37 days among survivors) after symptom onset10, but infectiousness may decline significantly 8 days after symptom onset, as live virus could no longer be cultured (according to Wölfel and colleagues11). Together, these results tư vấn our findings that the infectiousness profile may more closely resemble that of influenza than of SARS (Fig. 1a), although we did not have data on viral shedding before symptom onset6,12. Our results are also supported by reports of asymptomatic and presymptomatic transmission13,14.

For a reproductive number of 2.5 (ref. 2), contact tracing and isolation alone are less likely to be successful if more than 30% of transmission occurred before symptom onset, unless >90% of the contacts can be traced15. This is more likely achievable if the definition of contacts covers 2 to 3 days prior to symptom onset of the index case, as has been done in Hong Kong and mainland China since late February. Even when the control strategy is shifting away from containment to mitigation, contact tracing would still be an important measure, such as when there are super-spreading events that may occur in high-risk settings including nursing homes or hospitals. With a substantial proportion of presymptomatic transmission, measures such as enhanced personal hygiene and social distancing for all would likely be the key instruments for community disease control.

Our study has several limitations. First, symptom onset relies on patient recall after confirmation of COVID-19. The potential recall bias would probably have tended toward the direction of under-ascertainment, that is, delay in recognizing first symptoms. As long as these biases did not differ systematically between infector and infectee, the serial interval estimate would not be substantially affected. However, the incubation period would have been overestimated, and thus the proportion of presymptomatic transmission artifactually inflated. Second, shorter serial intervals than those reported here have been reported, but such estimates lengthened when restricted to infectorinfectee pairs with more certain transmission links16. Finally, the viral shedding dynamics were based on data for patients who received treatment according to nationally promulgated protocols, including combinations of antivirals, antibiotics, corticosteroids, immunomodulatory agents and Chinese medicine preparations, which could have modified the shedding dynamical patterns.

In conclusion, we have estimated that viral shedding of patients with laboratory-confirmed COVID-19 peaked on or before symptom onset, and a substantial proportion of transmission probably occurred before first symptoms in the index case. More inclusive criteria for contact tracing to capture potential transmission events 2 to 3 days before symptom onset should be urgently considered for effective control of the outbreak.

Methods

Sources of data

Guangzhou Eighth Peoples Hospital in Guangdong, China was designated as one of the specialized hospitals for treating patients with COVID-19 both city and provincial levels on 20 January 2022. After that, many people with COVID-19 were admitted via fever clinics, the hospital emergency room or after confirmation of cases from community epidemiological investigation carried out by the Guangzhou Center for Disease Control and Prevention, or transferred from other hospitals. The first confirmed patient with COVID-19 was admitted on 21 January 2022, but in the initial phase, patients suspected to have COVID-19 were also admitted. We identified all suspected and confirmed COVID-19 cases admitted from 21 January 2022 to 14 February 2022 and collected throat swabs in each case. Patients included those who traveled from Wuhan or Hubei to Guangzhou as well as locals, with cases ranging from asymptomatic, mild to moderate admission.

The samples were tested by N-gene-specific quantitative RTPCR assay as previously described17. To understand the temporal dynamics of viral shedding and exclude non-confirmed COVID-19 cases, we selected 94 patients who had least one positive result (cycle threshold (Ct) value < 40) in their throat samples. Serial samples were collected from some but not all patients for clinical monitoring purposes.

We collected information reported on possible human-to-human transmission pairs of patients with laboratory-confirmed COVID-19 from publicly available sources, including announcements made by government health agencies and truyền thông reports in mainland China and countries/regions outside China. A transmission pair was defined as two confirmed COVID-19 cases identified in the epidemiologic investigation by showing a clear epidemiologic link with each other, such that one case (infectee) was highly likely to have been infected by the other (infector), by fulfilling the following criteria: (1) the infectee did not report a travel history to an area affected by COVID-19 or any contact with other confirmed or suspected COVID-19 cases except for the infector within 14 days before symptom onset; (2) the infector and infectee were not identified in a patient cluster where other COVID-19 cases had also been confirmed; and (3) the infector and infectee pair did not share a common source of exposure to a COVID-19 case or a place where there were COVID-19 case(s) reported. We excluded possible transmission pairs without a clear exposure history reported prior to symptom onset. Data of possible transmission pairs of COVID-19 were extracted, including age, sex, location, date of symptom onset, type or relationship between the pair cases and time of contact of the cases.

Statistical analysis

We analyzed two separate data setsclinical and epidemiologicto assess presymptomatic infectiousness. First, we assessed longitudinal viral shedding data from patients with laboratory-confirmed COVID-19 starting from symptom onset, where viral shedding during the first few days after illness onset could be compared with the inferred infectiousness. Second, the serial intervals from clear transmission chains, combined with information on the incubation period distribution, were used to infer the infectiousness profile, as described in the following.

We present SARS-CoV-2 viral loads in the throat swabs of each patient by day of symptom onset. To aid visualization, a smoothing spline was fitted to the Ct values to summarize the overall trend. Specifically, a generalized additive model, E(Y) = β0 + s(t), with an identity link was fitted, where Y are the Ct values, β0 is the intercept and s(t) is a cubic spline evaluated t days after symptom onset. We also compared the viral load by disease severity, age, sex and travel history from Hubei.

We fitted a gamma distribution to the transmission pairs data to estimate the serial interval distribution. We used a published estimate of the incubation period distribution to infer infectiousness with respect to symptom onset from the first 425 patients with COVID-19 in Wuhan with detailed exposure history1. We considered that infected cases would become infectious a certain time point before or after illness onset (tS1). Infectiousnessthat is, transmission probability to a secondary casewould then increase until reaching its peak (Fig. 1). The transmission sự kiện would occur time tI with a probability described by the infectiousness profile βc(tI  tS1) relative to the illness onset date, assuming a gamma distribution β(t) with a time shift c to allow for start of infectiousness c days prior to symptom onset; that is, βc(t) = β(t + c). The secondary case would then show symptoms time tS2, after the incubation period that is assumed to follow a lognormal distribution g(tS2  tI). Hence the observed serial intervals distribution f(tS2  tS1) would be the convolution between the infectiousness profile and incubation period distribution. We constructed a likelihood function based on the convolution, which was fitted to the observed serial intervals, allowing for the start of infectiousness around symptom onset and window of symptom onset (tS1l, tS1u), given by

$$Lleft( t_rmS1u,t_rmS1l,t_rmS2 right) = mathop intlimits_t_rmS1l^t_rmS1u mathop intlimits_ – infty ^t_rmS2 beta _c left( t_rmI – t_rmS1 right)g(t_rmS2 – t_rmI)rmdt_rmIrmdt_rmS1$$

A normalization factor can be added to account for the uncertainty in the symptom-onset dates of the index cases. Assuming a uniform distribution, the likelihood would differ only by a multiplicative constant and give the same estimates.

Parameters θ, including the gamma distribution parameters and the start of infectiousness, were estimated using maximum likelihood. The 95% CIs were obtained by bootstrapping with 1,000 replications. We also performed sensitivity analyses by fixing the start of infectiousness from days 5, 8 and 11 before symptom onset and inferred the infectiousness profile.

As an additional check, we simulated the expected serial intervals assuming the same aforementioned incubation period but two different infectiousness profiles, where infectiousness started on the same day and from 2 days before symptom onset, respectively. A recent study isolated live infectious SARS-CoV-2 virus from patients with COVID-19 up to 8 days after symptom onset11, thus we assumed the same duration of infectiousness. We also assumed that infectiousness peaked on the day of symptom onset. The timing of transmission to secondary cases was simulated according to the infectiousness profile using a lognormal and exponential distribution, respectively, where the serial intervals were estimated as the sum of the onset to transmission interval and the incubation period. We drew random samples for the transmission time relative to symptom onset of the infector TI  βc(t), and also the incubation period Tinc  f(t), then the simulated serial interval was TI + Tinc. We also performed simulation considering combinations of different infectiousness profiles, with start of infectiousness 7 days before to 3 days after symptom onset, and peak infectiousness also 7 days before to 3 days after symptom onset. We present the distribution of the serial intervals and proportion of negative serial intervals over 10,000 simulations.

All statistical analyses were conducted in R version 3.6.3 (R Development Core Team).

Ethics approval

Data collection and analysis were required by the National Health Commission of the Peoples Republic of China to be part of a continuing public health outbreak investigation.

Reporting Summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

Detailed transmission pairs data in this study are provided in the Supplementary Information and viral shedding data will be available upon request and approval by a data access committee. The data access committee comprises leadership of the Guangzhou Eighth Peoples Hospital and the Guangzhou Health Commission. There is no restriction to data access.

Code availability

We provided the code for generating Fig. 1c in the Supplementary Information and ://github/ehylau/COVID-19. Other codes are available upon request to the corresponding author.

Change history

    07 August 2022

    A Correction to this paper has been published: ://doi.org/10.1038/s41591-020-1016-z

References

1.

Li, Q.. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 11991207 (2022).

CAS Article Google Scholar

2.

Wu, J. T., Leung, K. & Leung, G. M. Nowcasting and forecasting the potential domestic and international spread of the 2022-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 395, 689697 (2022).

CAS Article Google Scholar

3.

Peiris, J. S. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 17671772 (2003).

CAS Article Google Scholar

4.

Pitzer, V. E., Leung, G. M. & Lipsitch, M. Estimating variability in the transmission of severe acute respiratory syndrome to household contacts in Hong Kong, China. Am. J. Epidemiol. 166, 355363 (2007).

Article Google Scholar

5.

Riley, S. et al. Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science 300, 19611966 (2003).

CAS Article Google Scholar

6.

Ip, D. K. et al. Viral shedding and transmission potential of asymptomatic and paucisymptomatic influenza virus infections in the community. Clin. Infect. Dis. 64, 736742 (2022).

PubMed Google Scholar

7.

Ganyani, T. et al. Estimating the generation interval for COVID-19 based on symptom onset data. Preprint medRxiv ://doi.org/10.1101/2022.03.05.20031815 (2022).

8.

Zou, L. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 382, 11771179 (2022).

Article Google Scholar

9.

To, K.K.-W. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. ://doi.org/10.1016/S1473-3099(20)30196-1 (2022).

10.

Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 10541062 (2022).

CAS Article Google Scholar

11.

Wölfel, R. et al. Virological assessment of hospitalized patients with COVID-2022. Nature ://doi.org/10.1038/s41586-020-2196-x (2022).

12.

Tsang, T. K. et al. Influenza A virus shedding and infectivity in households. J. Infect. Dis. 212, 14201428 (2015).

Article Google Scholar

13.

Bai, Y. et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA ://doi.org/10.1001/jama.2022.2565 (2022).

14.

Tong, Z. D. et al. Potential presymptomatic transmission of SARS-CoV-2, Zhejiang Province, China, 2022. Emerg. Infect. Dis.://doi.org/10.3201/eid2605.200198 (2022).

15.

Hellewell, J. et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob. Health 8, e488e496 (2022).

Article Google Scholar

16.

Nishiura, H., Linton, N. M. & Akhmetzhanov, A. R. Serial interval of novel coronavirus (COVID-19) infections. Int. J. Infect. Dis. 93, 284286 (2022).

CAS Article Google Scholar

17.

Chen, W. et al. Detectable 2022-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg. Microbes Infect. 9, 469473 (2022).

CAS Article Google Scholar

Download references

Acknowledgements

This work was supported by Department of Science and Technology of Guangdong Province (project no. 2020B111108001, to F.L.) and a commissioned grant from the Health and Medical Research Fund from the Government of the Hong Kong Special Administrative Region (to B.J.C.).

Author information

Author notes

These authors contributed equally: Xi He, Eric H. Y. Lau.

These authors jointly supervised this work: Benjamin J. Cowling, Fang Li, Gabriel M. Leung.

Affiliations

Guangzhou Eighth Peoples Hospital, Guangzhou Medical University, Guangzhou, China

Xi He,Xilong Deng,Jian Wang,Yujuan Guan,Xinghua Tan,Xiaoneng Mo,Yanqing Chen,Baolin Liao,Weilie Chen,Fengyu Hu,Qing Zhang,Mingqiu Zhong,Yanrong Wu,Lingzhai Zhao,Fuchun Zhang&Fang Li

World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, University of Hong Kong, Hong Kong, SAR, China

Eric H. Y. Lau,Peng Wu,Xinxin Hao,Yiu Chung Lau,Jessica Y. Wong,Benjamin J. Cowling&Gabriel M. Leung

AuthorsXi HeView author publications

You can also search for this author in PubMedGoogle Scholar

Eric H. Y. LauView author publications

You can also search for this author in PubMedGoogle Scholar

Peng WuView author publications

You can also search for this author in PubMedGoogle Scholar

Xilong DengView author publications

You can also search for this author in PubMedGoogle Scholar

Jian WangView author publications

You can also search for this author in PubMedGoogle Scholar

Xinxin HaoView author publications

You can also search for this author in PubMedGoogle Scholar

Yiu Chung LauView author publications

You can also search for this author in PubMedGoogle Scholar

Jessica Y. WongView author publications

You can also search for this author in PubMedGoogle Scholar

Yujuan GuanView author publications

You can also search for this author in PubMedGoogle Scholar

Xinghua TanView author publications

You can also search for this author in PubMedGoogle Scholar

Xiaoneng MoView author publications

You can also search for this author in PubMedGoogle Scholar

Yanqing ChenView author publications

You can also search for this author in PubMedGoogle Scholar

Baolin LiaoView author publications

You can also search for this author in PubMedGoogle Scholar

Weilie ChenView author publications

You can also search for this author in PubMedGoogle Scholar

Fengyu HuView author publications

You can also search for this author in PubMedGoogle Scholar

Qing ZhangView author publications

You can also search for this author in PubMedGoogle Scholar

Mingqiu ZhongView author publications

You can also search for this author in PubMedGoogle Scholar

Yanrong WuView author publications

You can also search for this author in PubMedGoogle Scholar

Lingzhai ZhaoView author publications

You can also search for this author in PubMedGoogle Scholar

Fuchun ZhangView author publications

You can also search for this author in PubMedGoogle Scholar

Benjamin J. CowlingView author publications

You can also search for this author in PubMedGoogle Scholar

Fang LiView author publications

You can also search for this author in PubMedGoogle Scholar

Gabriel M. LeungView author publications

You can also search for this author in PubMedGoogle Scholar

Contributions

X. He, E.H.Y.L., P.W., B.J.C., F.L. and G.M.L. conceived and designed the study. X. He, X.D., J.W., Y.G., X.T., X.M., Y.C. and B.L. were responsible for clinical care and collected all biomaterials. W.C. and F.H. carried out laboratory testing. Q..Z., M.Z. and Y.W. collected and collated linked clinicalepidemiologic data. L.Z., F.Z. and F.L. supervised and coordinated all aspects of the study Guangzhou Eighth Peoples Hospital. P.W., X. Hao, Y.C.L. and J.Y.W. collected and verified all infectorinfectee transmission data. E.H.Y.L., B.J.C. and G.M.L. wrote the first draft. All authors contributed to data interpretation, critical revision of the manuscript and approved the final version of the manuscript.

Corresponding author

Correspondence to Eric H. Y. Lau.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information Alison Farrell and João Monteiro were the primary editors on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Publishers note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 Inferred infectiousness profile.

Infectiousness was assumed to start from 5 days (top) to 8 days (middle) and 11 days (bottom) before symptom onset.

Extended Data Fig. 2 Simulated serial intervals.

Simulated serial intervals assuming infectiousness started on the same day of symptom onset (top panel) and from 2 days before symptom onset (bottom panel) to about 10 days after symptom onset. Both scenarios assumed that infectiousness peaked on the first day of symptom onset.

Extended Data Fig. 3 Simulated proportions of negative serial intervals.

Simulated proportions of negative serial intervals assuming start of infectiousness and peak infectiousness from 7 days before symptom onset to 3 days after symptom onset. From the estimated serial interval distribution based on infector-infectee pairs, 7.6% of the serial intervals were negative. Gray area represents the implausible range where the peak infectious is earlier than the start of infectiousness.

Supplementary information

Supplementary Information

Supplementary Tables 13

Reporting Summary

Supplementary Data 1

Dataset for Fig. 1c.

Supplementary Software 1

R script for Fig. 1c.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

He, X., Lau, E.H.Y., Wu, P. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 26, 672675 (2022). ://doi.org/10.1038/s41591-020-0869-5

Download citation

    Received: 15 March 2022

    Accepted: 01 April 2022

    Published: 15 April 2022

    Issue Date: 01 May 2022

    DOI: ://doi.org/10.1038/s41591-020-0869-5

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative

Further reading

    Preventing COVID-19 outbreaks through surveillance testing in healthcare facilities: a modelling study

      Tim LitwinJens TimmerClemens Kreutz

    BMC Infectious Diseases (2022)

    Optimal strategies to screen health care workers for COVID-19 in the US: a cost-effectiveness analysis

      Sigal MayaGuntas PaddaJames G. Kahn

    Cost Effectiveness and Resource Allocation (2022)

    Modelling upper respiratory viral load dynamics of SARS-CoV-2

      Joseph D. ChallengerCher Y. FooAubrey J. Cunnington

    BMC Medicine (2022)

    Model-based evaluation of alternative reactive class closure strategies against COVID-19

      Quan-Hui LiuJuanjuan ZhangMarco Ajelli

    Nature Communications (2022)

    SARS-CoV-2 viability on sports equipment is limited, and dependent on material composition

      Thomas EdwardsGrant A. KayEmily R. Adams

    Scientific Reports (2022)

4241

Review Virus shedding là gì ?

Bạn vừa đọc tài liệu Với Một số hướng dẫn một cách rõ ràng hơn về Clip Virus shedding là gì tiên tiến và phát triển nhất

Chia Sẻ Link Download Virus shedding là gì miễn phí

Hero đang tìm một số trong những Share Link Down Virus shedding là gì Free.

Thảo Luận vướng mắc về Virus shedding là gì

Nếu sau khi đọc nội dung bài viết Virus shedding là gì vẫn chưa hiểu thì hoàn toàn có thể lại Comment ở cuối bài để Admin lý giải và hướng dẫn lại nha
#Virus #shedding #là #gì